Epigenomics AG
EPGNFOTCHealthcare● Active
$1.12
+$0.00(+0.00%)
Market Cap$982183
P/E Ratio—
52W High$1.12
52W Low$0.79
Epigenomics AG (EPGNF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EPGNF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Mar 14, 2024EPS Actual
$2.42
Revenue
$0.00B
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Mar 14, 2024
After Market Close
EPGNF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2025 | Apr 29, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Jan 21, 2025 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Sep 30, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Jul 22, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 29, 2024 | — | — | — | — | — | — |
| — Q1 FY2024 | Mar 14, 2024 | — | $2.42 | — | $0.00B | — | — |
| — Q3 FY2023 | Sep 30, 2023 | — | $2.32 | — | $0.00B | — | — |
| — Q3 FY2023 | Aug 8, 2023 | — | -$3.37 | — | $0.00B | — | — |
Q2 FY2025
Apr 29, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Jan 21, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Sep 30, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Jul 22, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 29, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 14, 2024
EPS Actual
$2.42
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2023
Sep 30, 2023
EPS Actual
$2.32
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2023
Aug 8, 2023
EPS Actual
-$3.37
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2024 | Mar 14, 2024 | — | $0.50 | $0.50 | +0.00% |
| — Q3 FY2023 | Sep 30, 2023 | — | $0.65 | $0.65 | +0.00% |
| — Q3 FY2023 | Aug 8, 2023 | — | $0.65 | $0.65 | +0.00% |
| — Q2 FY2023 | May 31, 2023 | — | $0.72 | $0.72 | +0.00% |
| — Q2 FY2023 | Apr 28, 2023 | — | $0.69 | $0.69 | +0.00% |
| — Q4 FY2022 | Nov 9, 2022 | — | $0.24 | $0.24 | +0.00% |
| — Q3 FY2022 | Aug 10, 2022 | — | $0.39 | $0.39 | +0.00% |
Q1 FY2024+0.00%
Report Date
Mar 14, 2024
EPS Beat/Miss
—
Price Before
$0.50
Price After
$0.50
Q3 FY2023+0.00%
Report Date
Sep 30, 2023
EPS Beat/Miss
—
Price Before
$0.65
Price After
$0.65
Q3 FY2023+0.00%
Report Date
Aug 8, 2023
EPS Beat/Miss
—
Price Before
$0.65
Price After
$0.65
Q2 FY2023+0.00%
Report Date
May 31, 2023
EPS Beat/Miss
—
Price Before
$0.72
Price After
$0.72
Q2 FY2023+0.00%
Report Date
Apr 28, 2023
EPS Beat/Miss
—
Price Before
$0.69
Price After
$0.69
Q4 FY2022+0.00%
Report Date
Nov 9, 2022
EPS Beat/Miss
—
Price Before
$0.24
Price After
$0.24
Q3 FY2022+0.00%
Report Date
Aug 10, 2022
EPS Beat/Miss
—
Price Before
$0.39
Price After
$0.39
Beat Rate0 / 7 quarters
Largest Move+0.00% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EPGNF ends December
Epigenomics AG (EPGNF) most recently reported earnings on March 14, 2024 for Q1 FY2024, posting EPS of $2.42 (in line with the analyst consensus of —). The next EPGNF earnings date is expected around September 1, 2026.
Each quarter, investors track EPGNF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EPGNF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EPGNF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EPGNF earnings · 4 questionsEpigenomics AG's next earnings report is expected around September 1, 2026. EPGNF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EPGNF historically reports after market close (AMC).
EPGNF earnings datewhen is EPGNF earningsEPGNF next earnings datewhen does EPGNF report earningsEPGNF earnings calendar
▸ Source: FMP · Epigenomics AG SEC filings · US GAAP · Epigenomics AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026